UMass Amherst Allows Maine-based ImmuCell Corp. the Right to License New Bacteriocin Technology

AMHERST, Mass. – The ImmuCell Corp. of Portland, Maine, announced today that it has entered into an exclusive agreement to license new bacteriocin technology from the University of Massachusetts Amherst, developed by biologist Margaret Riley and colleagues, internationally recognized researchers in antibiotics.

This technology focuses on bacteriocins, which are toxins that bacteria produce to attack other closely related bacteria. In particular, ImmuCell will focus on those that are active against gram negative strains that cause mastitis in dairy cattle, an infection the company calls the most significant cause of economic loss to the dairy industry. The collaboration will broaden the company’s pipeline of bacteriocin molecules that provide an alternative to traditional antibiotics.

Riley says, “I am delighted with our collaboration with ImmuCell, a company that shares our vision of a 21st century antibiotic arsenal rich with drugs that target the infecting agents, while leaving the commensal microbiome intact and thus reducing the selective intensity for antibiotic resistance.”

Read the News & Media Relations article here.

Current News | News Archive